Zoledronic acid protects against osteosarcoma-induced bone destruction but lacks efficacy against pulmonary metastases in a syngeneic rat model

International Journal of Cancer

Volumn 127, Issue 2, 2010, Pages 345-354

  Labrinidis, Agatha ^a   Hay, Shelley ^a   Liapis, Vasilios ^a   Findlay, David M ^a   Evdokiou, Andreas ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Bisphosphonate; Metastasis; Osteolysis; Osteosarcoma; Zoledronic acid

Indexed keywords

ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; CASPASE; IMIDAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE DESTRUCTION; CANCER GROWTH; CELL TRANSPLANTATION; CELL VIABILITY; CONTROLLED STUDY; CORTICAL BONE; DRUG EFFICACY; DRUG SAFETY; HISTOPATHOLOGY; LUNG METASTASIS; MALE; NONHUMAN; OSTEOSARCOMA; PERIOSTEUM; PRIORITY JOURNAL; RAT; TRABECULAR BONE; TREATMENT DURATION; TUMOR VOLUME; ANIMAL; BONE TUMOR; CELL PROLIFERATION; DRUG EFFECT; FISCHER 344 RAT; LUNG TUMOR; METABOLISM; METASTASIS; OSTEOLYSIS; PATHOLOGY; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BONE RESORPTION; CASPASES; CELL PROLIFERATION; DIPHOSPHONATES; IMIDAZOLES; LUNG NEOPLASMS; MALE; OSTEOSARCOMA; RATS; RATS, INBRED F344;

EID: 77953690136     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25051     Document Type: Article

References (43)

1. Campanacci M. Bone and soft tissue tumors, 2nd edn. Padova: Piccin Nuova Libraria, 1999.
2. Pringle JAS. Bone-forming neoplasms arising within bone. In: Helliwell TR, ed. Pathology of bone and joint neoplasmsed. Philadelphia: Saunders, 1999; p. 168-92.
3. Picci P. Osteosarcoma (Osteogenic sarcoma). Orphanet J Rare Dis 2007;2:6.
4. Chan HS, Grogan TM, Haddad G, DeBoer G, Ling V. P-glycoprotein expression: critical determinant in the response to osteosarcoma chemotherapy. J Natl Cancer Inst 1997;89:1706-15. (Pubitemid 27508195)
5. Ferrari S, Palmerini E. Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma. Curr Opin Oncol 2007;19:341-6. (Pubitemid 46883523)
6. Khanna C. Novel targets with potential therapeutic applications in osteosarcoma. Curr Oncol Rep 2008;10:350-8.
7. Link MP, Goorin AM, Horowitz M, Meyer WH, Belasco J, Baker A, Ayala A, Shuster J. Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the multi-institutional osteosarcoma study. Clin Orthop Relat Res 1991;270:8-14.
8. Longhi A, Errani C, De Paolis M, Mercuri M, Bacci G. Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev 2006;32:423-36. (Pubitemid 44309249)
9. Saeter G, Alvegard TA, Elommaa I, Wiebe T, Bjork O, Strander H, Solheim OP. Chemotherapy for osteosarcoma and Ewings sarcoma. Acta Orthop Scand Suppl 1997;273:120-5.
10. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002;2:584-93.
11. Chirgwin JM, Guise TA. Molecular mechanisms of tumor-bone interactions in osteolytic metastases. Crit Rev Eukaryot Gene Expr 2000;10:159-78.
12. Goltzman D. Mechanisms of the development of osteoblastic metastases. Cancer 1997;80:1581-7.
13. Goltzman D, Karaplis AC, Kremer R, Rabbani SA. Molecular basis of the spectrum of skeletal complications of neoplasia. Cancer 2000;88:2903-8. (Pubitemid 30413171)
14. Body JJ. Current and future directions in medical therapy: hypercalcemia. Cancer Cell 2000;88:3054-8.
15. Zhang FL, Casey PJ. Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 1996;65:241-69.
16. Kimura S, Kuroda J, Segawa H, Sato K, Nogawa M, Yuasa T, Ottmann OG, Maekawa T. Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines. Int J Hematol 2004;79:37-43. (Pubitemid 38182199)
17. Senaratne SG, Colston KW. Direct effects of bisphosphonates on breast cancer cells. Breast Cancer Res 2002;4:18-23. (Pubitemid 34097552)
18. Lee MV, Fong EM, Singer FR, Guenette RS. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 2001;61:2602-8.
19. Benassi MS, Chiechi A, Ponticelli F, Pazzaglia L, Gamberi G, Zanella L, Manara MC, Perego P, Ferrari S, Picci P. Growth inhibition and sensitization to cisplatin by zoledronic acid in osteosarcoma cells. Cancer Lett 2007;250:194-205. (Pubitemid 46529443)
20. Evdokiou A, Labrinidis A, Bouralexis S, Hay S, Findlay DM. Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikis. Bone 2003;33:216-28. (Pubitemid 37117133)
21. Farese JP, Ashton J, Milner RAL, Van Gilder J. The effect of the bisphosphonate alendronate on viability of canine osteosarcoma cells in vitro. In Vitro Cell Dev Biol Anim 2004;40:113-17. (Pubitemid 39096227)
22. Kubista B, Trieb K, Sevelda F, Toma C, Arrich F, Heffeter P, Elbling L, Sutterluty H, Scotlandi K, Kotz R, Micksche M, Berger W. Anticancer effects of zoledronic acid against human osteosarcoma cells. J Orthop Res 2006;24:1145-52. (Pubitemid 43870876)
23. Labrinidis A, Hay S, Liapis V, Ponomarev V, Findlay D, Evdokiou A. Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model. Clin Cancer Res 2009;15:3451-61.
24. Coleman R. On the horizon: can bisphosphonates prevent bone metastases? Breast 2007;16:21-7.
25. Green JR. Bisphosphonates: preclinical review. Oncologist 2004;9:3-13.
26. Winter MC, Holen I, Coleman RE. Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev 2008;34:453-75.
27. Corey E, Brown LG, Quinn JE, Poot M, Roudier MP, Higano CS, Vessella RL. Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res 2003;9:295-306. (Pubitemid 36109746)
28. Ali SM, Esteva FJ, Hortobagyi G, Harvey H, Seaman J, Knight R, Costa L, Lipton A. Safety and efficacy of bisphosphonates beyond 24 months in cancer patients. J Clin Oncol 2001;19:3434-7. (Pubitemid 32642197)
29. Wutzl A, Eisenmenger G, Hoffmann M, Czerny C, Moser D, Pietschmann P, Ewers R, Baumann A. Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients. Wien Klin Wochenschr 2006;118:473-8. (Pubitemid 44407466)
30. Heymann D, Ory B, Blanchard F, Heymann MF, Coipeau P, Charrier C, Couillaud S, Thiery JP, Gouin F, Redini F. Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma. Bone 2005;37:74-86. (Pubitemid 40848420)
31. Ory B, Heymann MF, Kamijo A, Gouin F, Heymann D, Redini F. Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice. Cancer 2005;104:2522-9. (Pubitemid 41691577)
32. Takahashi K, Sato K, Egami F, Miya T, Narukawa Y, Kanazawa H. Comparison of osteoblastic markers of nine clonal cell lines from rat osteosarcoma cells. J Bone Miner Metab 1991;9:241-7.
33. Daubine F, Le Gall C, Gasser J, Green JR, Clezardin P. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst 2007;99:322-30. (Pubitemid 47073494)
34. Cheng YY, Hueng L, Lee KM, Li K, Kumta SM. Alendronate regulates cell invasion and MMP-2 secretion in human osteosarcoma cell lines. Pediatr Blood Cancer 2004;42:410-15. (Pubitemid 38524469)
35. Sonnemann J, Eckervogt V, Truckenbrod B, Boos J, Winkelmann W, van Valen F. The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth in vitro. Anticancer Drugs 2001;12:459-65. (Pubitemid 32643090)
36. Koto K, Horie N, Kimura S, Murata H, Sakabe T, Matsui T, Watanabe M, Adachi S, Maekawa T, Fushiki S, Kubo T. Clinically relevant dose of zoledronic acid inhibits spontaneous lung metastasis in a murine osteosarcoma model. Cancer Lett 2009;274:271-8.
37. Dass C, Choong P. Zoledronic acid inhibits osteosarcoma growth in an orthotopic model. Mol Cancer Ther 2007;6:3263-70.
38. Buijs J, Que I, Lowik C, Papapoulos S, van der Pluijm G. Inhibition of bone resorption and growth of breast cancer in the bone microenvironment. Bone 2009;44:380-6.
39. Kabelitz D, Wesch D, Pitters E, Zoller M. Characterization of tumor reactivity of human V gamma 9V delta 2 gamma delta T cells in vitro and in SCID mice in vivo. J Immunol 2004;173:6767-76. (Pubitemid 39541063)
40. Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony H, Wilhelm M. Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 2000;96:384-92. (Pubitemid 30463353)
41. Lopez R. Human gammadelta-T cells in adoptive immunotherapy of malignant and infectious diseases. Immunol Res 2002;26:207-21. (Pubitemid 35177498)
42. Sato K, Kimura S, Segawa H, Yokota A, Matsumoto S, Kuroda J, Nogawa M, Yuasa T, Kiyono Y, Wada H, Maekawa T. Cytotoxic effects of gammadelta T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy. Int J Cancer 2005;116:94-9. (Pubitemid 40827760)
43. Wilhelm M, Kunzmann V, Eckstein S, Reimer P, Weissinger F, Ruediger T, Tony H. Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood 2003;102:200-6.